Correlation Between Novo Nordisk and Entia Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Novo Nordisk and Entia Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Novo Nordisk and Entia Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Novo Nordisk AS and Entia Biosciences, you can compare the effects of market volatilities on Novo Nordisk and Entia Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Novo Nordisk with a short position of Entia Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Novo Nordisk and Entia Biosciences.

Diversification Opportunities for Novo Nordisk and Entia Biosciences

-0.79
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Novo and Entia is -0.79. Overlapping area represents the amount of risk that can be diversified away by holding Novo Nordisk AS and Entia Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entia Biosciences and Novo Nordisk is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Novo Nordisk AS are associated (or correlated) with Entia Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entia Biosciences has no effect on the direction of Novo Nordisk i.e., Novo Nordisk and Entia Biosciences go up and down completely randomly.

Pair Corralation between Novo Nordisk and Entia Biosciences

If you would invest  10,980  in Novo Nordisk AS on September 5, 2024 and sell it today you would lose (40.00) from holding Novo Nordisk AS or give up 0.36% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Novo Nordisk AS  vs.  Entia Biosciences

 Performance 
       Timeline  
Novo Nordisk AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.
Entia Biosciences 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Entia Biosciences are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile technical and fundamental indicators, Entia Biosciences displayed solid returns over the last few months and may actually be approaching a breakup point.

Novo Nordisk and Entia Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Novo Nordisk and Entia Biosciences

The main advantage of trading using opposite Novo Nordisk and Entia Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Novo Nordisk position performs unexpectedly, Entia Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entia Biosciences will offset losses from the drop in Entia Biosciences' long position.
The idea behind Novo Nordisk AS and Entia Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Complementary Tools

Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Technical Analysis
Check basic technical indicators and analysis based on most latest market data